More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$539344108
EPS
-4.19
P/E ratio
--
Price to sales
7.48
Dividend yield
--
Beta
1.748117
Previous close
$8.50
Today's open
$8.58
Day's range
$8.10 - $8.66
52 week range
$5.37 - $18.22
show more
CEO
Jason Kelly
Employees
485
Headquarters
Boston, MA
Exchange
New York Stock Exchange
Shares outstanding
64825013
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.
The Motley Fool • Nov 7, 2026

Ginkgo Bioworks Q3 Earnings Call Highlights
Ginkgo Bioworks NYSE: DNA reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous laboratory systems and cloud-based lab services.
MarketBeat • Nov 7, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. Third Quarter 2026 Financial Results Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year perio.
Business Wire • Nov 5, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
Zacks Investment Research • Oct 29, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
Zacks Investment Research • Oct 20, 2026

Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
Zacks Investment Research • Oct 14, 2026

What's Going on With Ginkgo Bioworks Stock on Friday?
Ginkgo Bioworks Inc. (NYSE:DNA) is strengthening national biotechnology infrastructure by granting remote laboratory access through the National Science Foundation's X-Labs program and integrating high-speed cellular imaging tools into its Boston facility.
Benzinga • Oct 9, 2026

Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston.
PRNewsWire • Oct 8, 2026

Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs program. Ginkgo's support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C. NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engin.
Business Wire • Oct 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Ginkgo Bioworks Holdings Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.